Kura/Kyowa Kirin’s Ziftomenib Scores In NPM1m AML, But Differentiation Is Key

Kura Oncology and Kyowa Kirin plan to pursue US Food and Drug Administration approval based on positive Phase II topline results for ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia (AML), but there are still questions that remain as to how they can differentiate it from other menin inhibitors like Syndax Pharmaceuticals’ first-in-class Revuforj (revumenib), which recently hit the market.

The companies announced 5 February positive topline results from the Phase II KOMET-001 trial of ziftomenib, a once-daily oral menin...